Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
AstraZeneca
Baxter
Dow

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,974,802

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,974,802
Title:Medicament for the treatment of cancer of the pancreas
Abstract: The invention relates to a suspension of red corpuscles encapsulating asparaginase as a medicament for treating pancreatic cancer. It in particular concerns a therapeutic composition or medicament intended for the treatment of pancreatic cancer, containing an effective quantity of such a suspension of red corpuscles.
Inventor(s): Dufour; Emmanuelle-Cecile (Lyons, FR), Godfrin; Yann (Lyons, FR)
Assignee: Erytech Pharma (Lyons, FR)
Application Number:12/810,164
Patent Claims:1. A method for the treatment of pancreatic cancer, which comprises the administration to a human patient with pancreatic cancer of an effective dose of a suspension of red corpuscles encapsulating asparaginase.

2. The method according to claim 1, wherein the suspension contains between 30 and 300 IU of asparaginase per ml.

3. The method according to claim 1, wherein the suspension contains between 70 and 150 IU of asparaginase per ml.

4. The method according to claim 1, wherein the suspension has a volume of 10 to 250 ml.

5. The method according to claim 1, wherein one administers from 20 to 500 IU of asparaginase per kg body weight and per dose.

6. The method according to claim 1, wherein one administers from 50 to 500 IU of asparaginase per kg body weight and per dose.

7. The method according to claim 1, which comprises the administration to a patient in need thereof of an effective dose of a suspension of red corpuscles encapsulating asparaginase and of a chemotherapeutic agent.

8. The method according to claim 7, wherein the chemotherapeutic agent is selected from the group consisting of gemcitabine, cisplatin, oxaliplatin and combination of 5-fluorouracil with a platinum derivative.

9. The method according to claim 7, wherein the 5-fluorouracil is in combination with a platinum derivative selected from the group consisting of cisplatin and oxaliplatin.

10. The method according to claim 7, wherein the chemotherapeutic agent is formulated in the suspension of red corpuscles.

11. The method according to claim 7, wherein the chemotherapeutic agent and the suspension are administered to the patient by separate, concomitant or staggered administration.

12. The method for according to claim 1, wherein the suspension of red corpuscles encapsulating asparaginase is administered to the patient having a pancreatic cancer, in order to increase patient survival.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France07 60345Dec 24, 2007
PCT Information
PCT FiledDecember 24, 2008PCT Application Number:PCT/EP2008/068289
PCT Publication Date:July 02, 2009PCT Publication Number:WO2009/080837

Details for Patent 8,974,802

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Erytech Pharma (Lyons, FR) 2027-12-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
AstraZeneca
Johnson and Johnson
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.